Children’s Hospital of Philadelphia researchers compared the sequence data of more than 100,000 people of European ancestry and found copy number variant (CNV) associations in four major disease categories: autoimmune, cardio-metabolic, oncologic, and neurological/psychiatric diseases.
The drink targets small DNA elements called plasmids that carry antibiotic resistance genes. By preventing these plasmids from replicating, the antibiotic resistance genes are displaced, effectively re-sensitizing the bacteria to antibiotics.
Biocept's Target Selector test enables physicians to identify the potential presence of NTRK fusions used to inform on treatment options.
The deals with each partner will initially focus on the KRAS G12C mutation as found in non-small cell lung cancer (NSCLC), which accounts for approximately 13% of all NSCLC cases.
The NextSeq 2000 and NextSeq 1000 are both designed to meet growing demand for clinical genomic data at reduced cost, while the collaboration with Roche is focused on advancing clinical diagnostics leveraging Illumina’s pan-cancer assay TruSight Oncology 500.
Led by ex-Illumina executives, Element’s founders believe its sequencing technology can reduce costs and inject more competition into a market dominated by their former employer.
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
Women whose plasma contained circulating tumor DNA had only a 56% chance of being cancer-free two years following chemotherapy and surgery, while those without it had an 81% chance the cancer would not return in the same time span.
The two companies will look to develop a kitted NGS solution for the identification of biomarkers using blood samples collected from patients enrolled in clinical trials.
GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.